Company news

Share this article:
Abbott Laboratories has announced plans to acquire Ibis Biosciences, the molecular diagnostics division of Isis Pharmaceuticals. Abbott invested $40 million in the company earlier this year, and will purchase all remaining equity for $175 million. 
 
Wyeth Pharmaceuticals has announced the acquisition of Thiakis Limitied, a privately held biotech based in the UK. Thiakis lead product candidate, TKS 1225, will potentially treat obesity and other co-morbidities. 
 
New England-based pharma research firm Charles River Laboratories will invest $20 million and create 60 jobs by expanding its Charleston, SC, operations.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Panel votes against painkiller

Panel chair Randall Flick said QRxPharma "had not provided sufficient evidence to support a claim that Moxduo is safer than morphine or oxycodone."

Amgen sales rose by 5% in Q1

But demand for Enbrel and Aranesp slipped.

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.